Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | PLX8394 in patients with advanced cancer: activity, safety and ctDNA

Filip Janku, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the activity, safety and circulating tumor DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer. Dynamic changes in plasma ctDNA using droplet digital PCR (ddPCR) and targeted next-generation sequencing (NGS) were compared to treatment outcomes and were predictive of clinical responses in patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).